Table 2.
Trails characteristics
| Author | Research type | Location | Numbers (E/C) | Mean age (E/C) | QL block group | TAP block group | Surgery type | Follow-up |
|---|---|---|---|---|---|---|---|---|
| Blanco et al | RCT | UAE | 38/38 | 30.2/31.3 | 0.125%bupivacaine (0.2 ml/kg) | 0.125%bupivacaine (0.2 ml/kg) | Cesarean delivery | 4 months |
| Oksuz et al | RCT | Turkey | 25/25 | 3.13/3.02 | 0.2% bupivacaine (0.5 ml/kg) | 0.2% bupivacaine (0.5 ml/kg) | Low abdominal surgery | 5 months |
| Han et al | RCT | China | 39/38 | 26.3/27.8 | 20 ml of ropivacaine (concentration of 0.25%) | 20 ml of ropivacaine (concentrationof0.25%) | Appendectomy | 2 months |
| Yousef et al | RCT | India | 30/30 | 56.5/50.7 | 20 ml ofbupivacaine (concentration of 0.25%) | 20 ml ofbupivacaine (concentration of 0.25%) | Total abdominal hysterectomy | 3 months |
| Kumar et al | RCT | Egypt | 35/35 | 39.2/38.4 | 20 ml of ropivacaine (concentration of 0.25%) | 20 ml of ropivacaine (concentration of 0.25%) | Low abdominal surgery | 2 months |
| Li et al | RCT | China | 40 /40 | 30/31 | 20 ml of ropivacaine (concentration of0.375%) | 20 ml of ropivacaine (concentration of0.375%) | Cesarean delivery | 4 months |
| Zhu et al | RCT | China | 30/30 | 51/52 | 20 ml of ropivacaine (concentration of 0.25%) | 20 ml of ropivacaine (concentration of 0.25%) | Total abdominal hysterectomy | 2 months |
| Baytar et al | RCT | Turkey | 54/53 | 46.4/48.1 | 20 ml ofbupivacaine (concentration of 0.25%) | 20 ml ofbupivacaine (concentration of 0.25%) | Laparoscopic cholecystectomy | 3 months |
E experimental groups, C controlled groups, RCT randomized controlled trials, QL quadratus lumborum, TAP transversus abdominis plane